News
If you’ve been taking Ozempic or Wegovy (both of which contain the active ingredient semaglutide), you might wonder, How long ...
Pointing to Ozempic as a paradigm shift, an elite rehab center is experimenting with GLP-1s to tame many forms of addiction.
Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...
2h
News-Medical.Net on MSNEffective weight loss achieved even with inconsistent GLP-1 accessPopular anti-obesity medications continue to be effective for weight loss even when availability and access is interrupted, ...
New research finds that men taking a GLP-1 for their obesity or type 2 diabetes often experience a rise in testosterone ...
Research indicates GLP-1 receptor agonists, like Ozempic, may elevate testosterone levels in men while promoting weight loss. A study presented at ENDO 2025 showed a significant increase in ...
Postmenopausal women on tirzepatide show lower weight loss than those typically seen with the obesity drug, but weight loss ...
Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...
Weight loss injections can help people lose more weight than with other methods of weight loss, including lifestyle changes ...
Women and older adults taking the anti-obesity drug semaglutide may be at higher risk for muscle loss, but higher protein intake may help prevent muscle loss in these patients, according to a small ...
12h
New Scientist on MSNYou don't need to take drugs like Ozempic consistently to lose weightPeople who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which may reassure users when the therapies are in short supply.
The Semaglutide market is projected to expand from US$ 27.15 billion in 2024 to US$ 61.7 billion by 2033, with a CAGR of 9.55% from 2025. Driven by rising obesity and type 2 diabetes incidences, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results